| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 06/01/2025 | 17:45 | GlobeNewswire Inc. | Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference | EU:VLA | Valneva SE |
| 19/12/2024 | 08:00 | GlobeNewswire Inc. | Valneva Successfully Expands Access to Asia for its Chikungunya Vaccine with Serum Institute of India | EU:VLA | Valneva SE |
| 04/12/2024 | 07:00 | GlobeNewswire Inc. | Valneva Announces Peer-Reviewed Publication on the Global Health and Economic Burden of Chikungunya in The British Medical Journal | EU:VLA | Valneva SE |
| 03/12/2024 | 07:00 | GlobeNewswire Inc. | Valneva Reports Positive Three-Year Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ® | EU:VLA | Valneva SE |
| 26/11/2024 | 17:45 | GlobeNewswire Inc. | Valneva Submits Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to the U.S. FDA | EU:VLA | Valneva SE |
| 13/11/2024 | 17:45 | GlobeNewswire Inc. | Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2 | EU:VLA | Valneva SE |
| 12/11/2024 | 07:00 | GlobeNewswire Inc. | Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences | EU:VLA | Valneva SE |
| 07/11/2024 | 07:00 | GlobeNewswire Inc. | Valneva Reports Nine-Month 2024 Financial Results and Provides Corporate Updates | EU:VLA | Valneva SE |
| 21/10/2024 | 17:45 | GlobeNewswire Inc. | Valneva to Present on Chikungunya at Several Leading Scientific Conferences | EU:VLA | Valneva SE |
| 16/10/2024 | 17:45 | GlobeNewswire Inc. | Valneva and LimmaTech Awarded FDA Fast Track Designation for Tetravalent Shigella Vaccine Candidate S4V | EU:VLA | Valneva SE |
| 10/10/2024 | 07:00 | GlobeNewswire Inc. | Valneva Hosts Investor Day in New York City | EU:VLA | Valneva SE |
| 03/10/2024 | 07:00 | GlobeNewswire Inc. | Valneva to Host Investor Day in New York on Thursday, October 10, 2024 at 10:00 AM ET | EU:VLA | Valneva SE |
| 18/09/2024 | 07:00 | GlobeNewswire Inc. | Valneva Submits Label Extension Applications for its Chikungunya Vaccine, IXCHIQ®, to EMA and Health Canada | EU:VLA | Valneva SE |
| 13/09/2024 | 08:30 | GlobeNewswire Inc. | Valneva Announces the Success of its Private Placement Raising approximately €60 Million | EU:VLA | Valneva SE |
| 03/09/2024 | 07:00 | GlobeNewswire Inc. | Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate | EU:VLA | Valneva SE |
| 13/08/2024 | 07:00 | GlobeNewswire Inc. | Valneva Reports Half Year 2024 Financial Results and Provides Corporate Updates | EU:VLA | Valneva SE |
| 01/08/2024 | 07:00 | GlobeNewswire Inc. | Valneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World’s Most Clinically Advanced Tetravalent Shigella Vaccine Candidate | EU:VLA | Valneva SE |
| 22/07/2024 | 07:00 | GlobeNewswire Inc. | CEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the World’s First Chikungunya Vaccine | EU:VLA | Valneva SE |
| 17/07/2024 | 22:00 | GlobeNewswire Inc. | Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion | EU:VLA | Valneva SE |
| 04/07/2024 | 18:00 | GlobeNewswire Inc. | Déclaration d’actions et de droits de vote - Valneva SE - 30 juin 2024 | EU:VLA | Valneva SE |
| 04/07/2024 | 18:00 | GlobeNewswire Inc. | Declaration of shares and voting rights - Valneva SE - June 30, 2024 | EU:VLA | Valneva SE |
| 01/07/2024 | 07:00 | GlobeNewswire Inc. | Valneva reçoit une autorisation de mise sur le marché en Europe pour le premier vaccin au monde contre le chikungunya, IXCHIQ® | EU:VLA | Valneva SE |
| 01/07/2024 | 07:00 | GlobeNewswire Inc. | Valneva Receives Marketing Authorization in Europe for the World’s First Chikungunya Vaccine, IXCHIQ® | EU:VLA | Valneva SE |
| 26/06/2024 | 17:45 | GlobeNewswire Inc. | Valneva annonce l’approbation des résolutions présentées à son Assemblée Générale et la nomination d’un nouvel administrateur à son conseil d’administration | EU:VLA | Valneva SE |
| 26/06/2024 | 17:45 | GlobeNewswire Inc. | Valneva Announces Successful Outcome of its Combined General Meeting and Appointment of a New Director to its Board | EU:VLA | Valneva SE |
| 24/06/2024 | 07:00 | GlobeNewswire Inc. | Valneva Announces Health Canada Approval of the World’s First Chikungunya Vaccine, IXCHIQ® | EU:VLA | Valneva SE |
| 24/06/2024 | 07:00 | GlobeNewswire Inc. | Valneva annonce l’approbation par Santé Canada du premier vaccin au monde contre le chikungunya, IXCHIQ® | EU:VLA | Valneva SE |
| 05/06/2024 | 07:00 | GlobeNewswire Inc. | Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update | EU:VLA | Valneva SE |
| 05/06/2024 | 07:00 | GlobeNewswire Inc. | Valneva annonce la mise à disposition des documents préparatoires à son Assemblée Générale Mixte et une évolution de son équipe de direction | EU:VLA | Valneva SE |
| 04/06/2024 | 18:00 | GlobeNewswire Inc. | VALNEVA - Déclaration d’actions et de droits de vote : 31 mai 2024 | EU:VLA | Valneva SE |